Background Concurrent testing for human papillomavirus (HPV) and cervical cytology (co-testing) is an approved alternative to cytology alone in women aged 30 years and older. We aimed to assess the safety in routine clinical practice of 3-year screening intervals for women testing negative for HPV with normal cytology and to assess if co-testing can identify women at high risk of cervical cancer or cervical intraepithelial neoplasia grade 3 (CIN3) or worse over 5 years.
Introduction
The fi ndings of long-term prospective cohort studies and randomised clinical trials have shown that DNA testing for human papillomavirus (HPV) is substantially more sensitive than cervical cytology for the detection of cervical intraepithelial neoplasia grade 2 (CIN2) and grade 3 (CIN3) and cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] Incorporation of testing for HPV into programmes screening for cervical cancer could reduce the incidence of this cancer in women aged 30 years and older [4] [5] 8, 10 (particularly for adenocarcinoma, the precursors of which are often missed by cytological methods 11 ), and even mortality. 12 Cohort studies and trials suggest that women's risk of CIN3 or cancer after a negative test for HPV is very low for 5 years.
3,10,13,14 These fi ndings were the basis for regulatory and clinical guideline approval 15, 16 of routine testing for HPV in conjunction with cervical cytology (co-testing) for cervical cancer screening of women aged 30 years and older. In particular, the guidelines discourage the screening of women with normal cytology (ie, negative by Pap testing) and negative for HPV before 3 years, to avoid the detection of new infections with HPV. New infections with HPV are associated with an extremely low risk of cancer because they usually resolve without the need for medical intervention. 17 Although promising and approved, co-testing has not been widely adopted in the USA. In a recent survey, 18 only 19% of US clinicians would recommend the 3-year screening interval for women with normal cytology testing who are negative for HPV, which suggests concern about the cancer risk accrued over 3 years. Studies in routine clinical practice are needed to estimate the feasibility and safety of co-testing guidelines. 19 Although clinical trials and research cohorts in specially selected populations can show effi cacy in specifi c, tightly controlled, idealised circumstances, the fi nal proof of the value of medical interventions is their eff ectiveness in general clinical practice, with all its attendant complexity, such as non-standard protocols, potential non-adherence by clinicians and patients to protocols, or screening tests done in non-ideal circumstances. Furthermore, very large samples are needed to establish actual cancer risks for each possible cytological abnormality and HPV test result, especially for women who are negative by HPV and cytology testing, for whom reassurance against cancer is the crucial factor for deciding their screening interval. Finally, each successive screen, if eff ective, 20, 21 should lower the subsequent population risk because those with previously evident and clinically relevant disease have already been identifi ed and treated, and therefore do not contribute to the overall risk. Therefore, extended follow-up of very large numbers of women negative for HPV or by Pap provides an opportunity to assess how much further their cancer risks decrease after their return in 3 years for their second visit, which has not been previously assessed.
In 2003, Kaiser Permanente Northern California (KPNC, Berkeley, CA, USA), a large health-maintenance organisation, adopted a screening programme for cervical cancer based on co-testing, with extended screening intervals for women with normal cytology who test negative for HPV. The KPNC experience serves as a large-scale demonstration project of what could realistically be achieved in routine clinical practice, where providers receive no special training and do not need any special qualifi cations to participate and that no provider, provider group, patient, or group of patients is excluded. We established the risk of cervical cancer for women aged 30 years and older who enrolled in co-testing at KPNC between 2003 and 2005. We also assessed the risk of cervical cancer after the second screening visit in women who were negative by both HPV and Pap testing at enrolment, to establish whether the second co-test provided additional reassurance against cancer. Our principal aims were to establish the safety of 3-year screening intervals for women negative by both HPV and Pap testing and the value of adding testing for HPV to cytology screening to earlier identify women at high risk of CIN3 or worse or cervical cancer over 3-5 years.
Methods

Participants
KPNC membership is demographically similar to the US Census-enumerated population in the Bay Area Metropolitan Statistical Area, except for lacking representation of extremes in income. 22, 23 In a study of the KPNC population including the women in this study, of the 49% of women who self-reported their race or ethnicity in KPNC, 62% were white, 12% were Asian/ Pacifi c islander, 12% were Hispanic, and 8% were African-American. 24 The KPNC population is thought a well-screened population, and their risk of cervical cancer has historically been lower than the national average 25 (most cancer cases in the USA are in regions where screening services are unavailable 26 ). Over 90% of eligible women enrolled in co-testing. 24 
Procedure
Conventional Pap tests were reported according to the 2001 Bethesda System 27 (in order of increasing severity): no intraepithelial lesion or malignancy (negative or normal by Pap test); atypical squamous-cells of undetermined signifi cance (ASC-US); low-grade squamous intraepithelial lesion (LSIL); atypical glandular cells of undetermined signifi cance or not otherwise specifi ed (AGUS/NOS); atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); high-grade squamous intraepithelial lesion (HSIL); or squamous-cell carcinoma (SCC). A positive Pap test means ASC-US or more severe cytology. We grouped ASC-H, HSIL, and SCC into a single high-risk Pap category because each is individually uncommon and their CIN3 or worse risks were similarly increased. Conventional Pap slides were manually reviewed after processing by the BD FocalPoint Slide Profi ler (BD Diagnostics, Burlington, NC, USA) primary screening and directed quality control system, in accordance with protocols approved by the US Food and Drug Administration. As an important methodological point, we note that a metaanalysis 28 and two large randomised trials 29, 30 have not shown any clinical performance advantage of liquidbased cytology over conventional Pap smears for detection of CIN3 or worse. Hybrid Capture 2 (HC2; Qiagen, Germantown, MD, USA) was used to test for the pool of carcinogenic HPV types according to manufacturer's instructions. HC2 has high interoperator reliability. 31 All cytology and testing for HPV was done at the Regional Laboratory of the Northern California Kaiser Permanente Medical Care Program by a stable staff of about 30 cytotechnicians, laboratory technicians, clinical scientists, and pathologists.
Histological fi ndings were classifi ed (in order of increasing severity) as no lesion found, CIN1, CIN2, CIN3, adenocarcinoma in situ, SCC, or adenocarcinoma. CIN2 or CIN3/adenocarcinoma in situ (AIS) histology was suffi cient to refer a woman for treatment by a loop electrosurgical excision procedure. All reported cervical cancers were verifi ed by chart review by WKK and J Thomas Cox (University of California Santa Barbara, CA, USA). Abnormal biopsies were reviewed and signed out by a stable team of about 60 pathologists in the 12 pathology departments of KPNC. We primarily focused on CIN3 or cancer rather than CIN2 or worse, because CIN2 is unreliably identifi ed by pathologists, 32 ,33 often regresses, 34, 35 and might simply relate to uncertainty between acute infection with HPV (CIN1) and CIN3. 36 However, our fi ndings did not appreciably change when we used CIN2 or worse as our endpoint (the webappendix pp 3-6 includes all risks for CIN2 or worse).
KPNC has its own management guidelines for patients, which are fairly consistent with the 2004 interim guidelines for HPV testing 15 and 2006 American Society for Colposcopy and Cervical Pathology guidelines, 16 and KPNC clinicians are asked to adhere to their guidelines. Women with LSIL or more severe cytology, irrespective of the HPV test result, were sent for colposcopy. Women with ASC-US who tested positive for HPV were sent to colposcopy, whereas those who tested negative for HPV were asked to return for a 1-year follow-up. Women who were negative by both HPV and Pap testing were asked to return for screening in 3 years. Until 2005, women positive for HPV but negative by Pap testing were generally monitored annually for cytological evidence of disease. After 2005, women with consecutive positive HPV results were off ered colposcopy. We had access to information about past history of an abnormal Pap test or abnormal biopsy predating the cotesting era at KPNC, but we could not independently verify the completeness of the information.
KPNC uses a computerised patient follow-up system, which reviews laboratory results daily and sets alarm fl ags for appropriate follow-up intervals for each abnormal result. If, for example, a biopsy has not been recorded after an abnormal Pap test within a given period, an alarm is sent to the personnel responsible for the screening system at the appropriate facility. If this condition is not reset by receipt of a biopsy within a given period, escalating alarms follow to the practitioner, then the Chief of Obstetrics and Gynaecology, and fi nally the Physician-in-Chief of the facility. If a woman loses her job, leaves northern California, or changes her health insurance from KPNC, her future records are unknown to KPNC.
Statistical analysis
We estimated the cumulative incidence of the outcomes CIN2 or worse, CIN3 or worse, or cervical cancer for each possible combination of HPV test and Pap smear result with SAS version 9.0. We estimated cumulative incidence from enrolment for all women, and after the fi rst return visit for women who co-tested negative by HPV test and Pap smear at enrolment. We defi ned cumulative incidence to include prevalence at enrolment and the incidence after enrolment. At screening visits only HPV test and Pap smear samples were collected. At biopsy visits, colposcopically directed biopsies were taken. The prevalence at enrolment was defi ned as the ratio of the number of women diagnosed with each outcome on the biopsy visit immediately after their enrolment screening visit to the total number of enrolled women. We used Weibull survival models 37 to estimate post-enrolment incidence, which make smoother and more accurate estimates, when the Weibull model holds, than nonparametric methods analogous to Kaplan-Meier. 38 We fi tted separate Weibull models to each co-test result. We also used Weibull regression models to assess if age and history of abnormal Pap smears or CIN2 or worse biopsies aff ect cumulative incidence from enrolment and, in women who tested negative by both HPV and Pap testing at enrolment, from the second screening visit. The webappendix (pp 1-2) gives additional details of our statistical methods.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The Intramural Research Program of the US National Institutes of Health and National Cancer Institute reviewed the fi nal manuscript for publication. The KPNC institutional review board (IRB) approved use of the data, and the National Institutes of Health Offi ce of Human Subjects Research deemed this study exempt from IRB review. HAK and PEC had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
We established the risk of CIN3 or cervical cancer for 331 818 women aged 30 and older who enrolled in co-testing at KPNC (table 1) . At enrolment, testing positive for HPV was slightly more common than having abnormal cytology (ASC-US or worse; 5·1% vs 3·8%, p<0·0001) and testing for HPV had slightly less specifi city than cytology (95·5% vs 96·5%, p<0·0001; table 1). However, higher percentages of disease outcomes (sensitivities) were identifi ed in the women positive for HPV at enrolment than in women positive by Pap for CIN2 (78% vs 53%, p<0·0001), CIN3 or adenocarcinoma in situ (84% vs 53%, p<0·0001), adenocarcinoma in situ (80% vs 40%, p<0·0001), total cancers (69% vs 51%, p=0·02), and adenocarcinoma (78% vs 15%, p<0·0001; table 1). Our comparison of discordant co-test results (negative HPV and positive Pap vs positive HPV and negative Pap) shows the relative importance of testing for HPV versus cytology. We identifi ed higher percentages of disease outcomes in women who were positive by HPV and negative by Pap than women who were negative by HPV and positive by Pap for CIN2 (29% vs 4%, p<0·0001), CIN3 or adenocarcinoma in situ (35% vs 4%, p<0·0001), adenocarcinoma in situ (44% vs 4%, p<0·0001), total cancers (29% vs 10%, p=0·004), and especially adenocarcinoma (63% vs 0%, p<0·0001; table 1). Figure 1A and the webappendix (pp 3-6) show that prevalent CIN3 or worse risks at enrolment were similar in women who were positive by HPV and Pap testing (2·1% vs 2·7%). However, enrolment HPV testing distinguished future risk of CIN3 or worse and cancer more clearly than enrolment cytology. Risk of CIN3 or worse was less in all women negative for HPV than in all women negative by Pap, not only for 3 years (0·063% vs 0·17%, p=0·001), but also for 5 years (0·17% vs 0·36%, p=0·02; fi gure 1). Women negative for HPV also had half the 5-year risk of invasive cervical cancer of women negative by Pap (3·8 vs 7·5 per 100 000 women per year; p=0·3). Conversely, risk of CIN3 or worse was greater in women positive for HPV than women positive by Pap, not only for 3 years (5·0% vs 3·8%, p=0·046), but also for 5 years (7·6% vs 4·7%, p=0·001; fi gure 1). Figure 1B and the webappendix (pp 3-6) shows that Pap smears further distinguished risk of CIN3 and cancer in women positive for HPV, but not women negative for HPV. Abnormal cytology substantially increased the risk of CIN3 or worse for all women positive for HPV not only for 3 years (10·0% vs 3·1%, p<0·0001) but also for 5 years (12·1% vs 5·9%, p<0·0001; fi gure 1). The HPV test more clearly separated high-risk women from low-risk women than the Pap smear because both women positive for HPV at enrolment had higher risk of CIN3 or worse than the women positive by Pap after 3 years (5·0% vs 3·8%, p=0·046) and 5 years (7·6% vs 4·7%, p=0·001), and women negative for HPV at enrolment had lower risk of CIN3 or worse than women negative by Pap at enrolment after 3 years (0·063% vs 0·17%, p=0·001) and after 5 years (0·17% vs 0·36%, p=0·02). (B) A positive Pap test strongly modifi ed risks for positive HPV at 3 years (10·0% vs 3·1%, p<0·0001) and 5 years (12·1% vs 5·9%, p<0·0001), but not for negative HPV either at 3 years (0·53% vs 0·047%, p<0·0001) or 5 years (0·86% vs 0·16%, p=0·004), although risks are statistically distinguishable. Comparing with A, also being negative by Pap did not reduce risk of CIN3 or worse from just being negative for HPV either at 3 years (0·047% vs 0·063%, p=0·6) or 5 years (0·16% vs 0·17%, p=0·8). The webappendix (pp 3-6) lists the 95% CIs for all risk estimates. HPV=human papillomavirus. CIN3=cervical intraepithelial neoplasia grade 3. The webappendix (p 7) shows that some risks of CIN3 or worse were strongly modifi ed by previous history of abnormalities and by age. Most notably, the already low Prevalent disease is plotted at time 0 (enrolment) and incident disease is plotted from that point. Although only 0·25% of women, women with ASC-H/HSIL/SCC Pap smears had by far the highest 3-year risks of CIN2 or worse (59%), CIN3 or worse (28%), and cancer (4·1%). Versus women with LSIL, women with HPV positive/ASC-US had higher 3-year risk of CIN2 or worse (21% vs 14%, p=0·01) and CIN3 or worse (6·4% vs 3·2%, p=0·03). Most women positive for HPV at enrolment (73%) were negative by Pap, and although they had by far the lowest disease risks at enrolment of any of the group positive for HPV (CIN2 or worse 0·36%, CIN3 or worse 0·16%, cancer 0·04%), they accrued 5-year risks post enrolment (CIN2 or worse 13%, CIN3 or worse 5·8%, cancer 0·5%) akin to women with ASC-H/HSIL/SCC (CIN2 or worse 14%, CIN3 or worse 6·1%, cancer 1·7%) or with HPV positive/ASC-US (CIN2 or worse 13%, CIN3 or worse 3·9%, cancer 0%; p=0·8 vs ASC-H/HSIL/SCC, p=0·7 vs HPV positive/ASC-US). Women positive for HPV but negative by Pap had higher 5-year cancer risk than women negative for HPV but positive by Pap (0·54% vs 0·16%, p=0·2). HPV negative/ ASC-US and women negative by both HPV and Pap testing had the smallest, and nearly indistinguishable, 5-year risks of CIN2 or worse (1·3% vs 0·54%, p=0·07) and CIN3 or worse (0·54% vs 0·16%, p=0·08). The 5-year cervical cancer risk in women who were negative by both HPV and Pap testing at enrolment was 0·016% (3·2 per 100 000 women per year), only slightly smaller than the 0·019% (3·8 per 100 000 per year) risk in the group negative for HPV at enrolment overall (p=0·8). By comparison, the 5-year cervical cancer risk in women negative by Pap was 0·037% (7·5 per 100 000 per year; p=0·3 vs cancer risk in women negative for HPV). On the per 100 000 women per year scale, the 5-year cancer risks are 3·2 for women negative by both HPV and Pap; 32 for women negative for HPV by positive by Pap; 108 for women positive for HPV but negative by Pap; 180 for women positive by both HPV and Pap testing. The webappendix (pp 3-6) lists the 95% CIs for all risk estimates. HPV=test for human papillomavirus. CIN2=cervical intraepithelial neoplasia grade 2. CIN3=cervical intraepithelial neoplasia grade 3. Screening for cervical cancer is a repetitive process, in which women that tested normal in previous screens are re-screened after a specifi ed interval. We also assessed the risk of CIN3 or cervical cancer after the second screening visit in 195 975 women who were negative by both HPV and Pap testing at enrolment (table 2), to establish whether the second co-test provided additional reassurance against cancer. Table 2 , fi gure 3, and the webappendix (pp [8] [9] [10] [11] show raw data and disease risks for the 195 975 women who were negative by both HPV and Pap testing at enrolment and returned for a second co-test (median of 2·9 years to return, IQR 2·3-3·2). The proportion of positive tests for HPV at the second screen was half the proportion at enrolment (2·8% vs 5·1%, p<0·0001 ; table 1 and table 2 ). The increase in the fraction or women positive by Pap (4·3% vs 3·8%, p<0·0001) was almost entirely due to an increase in HPV negative/ ASC-US (2·8% vs 2·0%, p<0·0001), the lowest-risk Pap-positive co-test. Most importantly, the distribution of the second co-test results was down-staged in severity from the distribution of enrolment co-tests: the total fraction of women negative by both HPV and Pap testing or HPV negative/ASC-US increased (96·8% vs 94·5%, p<0·0001), the fraction of women positive by HPV but negative by Pap was halved (1·7% vs 3·7%, p<0·0001), and the fraction HPV positive/ASC-US, LSIL, AGUS/NOS, or ASC-H/HSIL/SCC decreased (1·5% vs 1·9%, p<0·0001).
Moreover, the risks of CIN3 or worse in the years after positive screening tests at the second visit were lower than after positive screening tests at enrolment (fi gure 1A and fi gure 3A). Women who were positive for HPV at the second co-test after negative tests by both HPV and Pap at enrolment had notably reduced 3-year risk of CIN3 or worse than women who were positive for HPV at enrolment (3·0% vs 5·0%, p=0·09); we noted a similar pattern in women positive by Pap (1·3% vs 3·8%, p=0·04) . The 3-year risks were also lower for women positive by both HPV and Pap (5·1% vs 10·0%, p=0·3), positive for HPV but negative by Pap (1·8% vs 3·1%, p=0·3), and negative by HPV and positive by Pap co-tests (0·19% vs 0·53%, p=0·4) at second co-test after being negative by both HPV and Pap at enrolment than the respective risk of the same screening combinations at enrolment.
However, at the return visit after an enrolment negative co-test (fi gure 1B and fi gure 3B), 3-year risks of CIN3 or worse were not lower for women testing negative for HPV again (0·082% vs 0·063%, p=0·6), negative by Pap again (0·15% vs 0·17%, p=0·8), or negative by both HPV and Pap again (0·079% vs 0·047%, p=0·5) . Table 2 : Distribution of worst histological diagnosis since the second HPV test and Pap smear in women negative for both HPV and cytology at enrolment subsequent 3 years was also no lower in women who retested negative by both HPV and Pap (2·7 vs 3·0 per 100 000 women per year, p=0·9; webappendix pp 8-11).
Discussion
The KPNC co-testing programme provided us with an opportunity to assess the real-world clinical eff ectiveness of concurrent testing for HPV with cytology in a large and diverse US screening population followed up for several years. Women testing negative for HPV had low risk of CIN3 or cancer over 5 years, irrespective of normal cytology or minor abnormalities. Although women positive for HPV with cytological abnormalities had the highest risks, women positive for HPV with normal cytology accrued substantial risk of CIN3 or cancer over 5 years. Co-testing was less able to identify women at high risk at their second visit at about 3 years after an enrolment test negative by both HPV and Pap. Their cotest results were down-staged to safer co-tests and the risk of CIN3 or worse for each possible second co-test result was generally diminished from the risk associated with that co-test result at enrolment. Women negative by both HPV and Pap at enrolment had a low risk of cervical cancer of 3·2 per 100 000 women per year over 5 years. This risk is similar to the risk of vulvar cancer in northern California in women aged 30 years and older (3·1 per 100 000 women per year; SEER 2003-07), another potentially preventable cancer that is too rare to justify organised prevention. This fi nding supports lengthening the screening interval for women negative by both HPV and Pap to 5 years, as has already been done in many European countries. 39 The substantially lower risks of CIN3 or worse in women negative by both HPV and Pap aged 50 years or older (vs women aged 30-34 years), or for women negative by both HPV and Pap with no history of previous abnormal cytology, raise the possibility that some subgroups of these women could be safely screened at even longer intervals.
A single negative test for HPV was suffi cient to reassure a woman of extremely low risk of CIN3 or cancer for 5 years. We identifi ed that negative cytology provided no extra reassurance against cancer beyond that conferred by a negative HPV test result. The practically equal 5-year risks of CIN3 or cancer for women negative by both HPV and Pap and for women that are HPV negative/ASC-US suggests that women in this latter group could be safely screened in routine clinical practice at the same extended interval as women negative by both HPV and Pap. [40] [41] [42] Our fi ndings are consonant with the biological fact that carcinogenic HPV is involved in almost every cervical cancer. Finally, the low yields of LSIL or worse Pap smear (0·5%) and ASC-H/HSIL/SCC Pap smears (0·05%) in women negative for HPV might not be suffi cient to justify Pap smear tests for women negative for HPV. Our fi ndings strongly suggest that primary HPV testing, with a positive test for HPV triaged by cytology (or other tests with high specifi city), a strategy that might preserve nearly all the safety of co-testing while reducing the number of Pap tests by 95% in our population, could be more effi cient than co-testing-as has been suggested by others. 5, 13, 39, 43 Although cytological abnormalities suggested prevalent disease, testing for HPV predicted future disease much better than cytology. For example, women positive for HPV but negative by Pap, who were the majority of women positive for HPV (73%), had low prevalent disease risk at enrolment (in part because these women were rarely sent for immediate colposcopy), yet accrued substantial incident disease risks over 5 years that were similar to 44, 45 Thus, it is imperative to develop new biomarkers (such as HPV genotyping 42, 46 or P16-INK4a/ Ki67 immuno cyto chemistry 47 ) to better triage women positive for HPV but negative by Pap into fi ner risk categories, 48 especially risk of adenocarcinoma, whose incidence is on the rise in the USA. 49 We expected that the ability of co-testing to separate high-risk women from low-risk women would diminish at the second co-test in women negative by both HPV and Pap co-test at enrolment because there are always fewer high-risk women with prevalent CIN3 or worse at the second and subsequent screens. Therefore, women positive for HPV at the second co-test, about 3 years after a negative HPV and Pap test at enrolment, had lower risk of CIN3 or worse and cancer risks than women testing positive for HPV at enrolment. By contrast, a second consecutive negative test for HPV and Pap (at a median of 2·9 years after the fi rst) seemed to off er no detectable additional reassurance against CIN3 or cervical cancer than the fi rst negative co-test for HPV and Pap. Our fi ndings suggest that the common practice of yearly HPV testing for women negative for HPV just to be sure 18 is unnecessary and support guidelines [15] [16] that women negative for both HPV and Pap testing should not be rescreened before at least 3 years.
Although KPNC practices are not typical in many ways, because KPNC serves a large and diverse population involving providers without special qualifi cations or special training to participate, we believe that the KPNC experience serves as a large-scale demonstration project of what could realistically be achieved in real-life clinical practice. Consequently, non-compliance by clinicians or patients to protocols, imperfect diagnostic testing, and other imperfections are real-life complexities that should be incorporated into our risk estimates. The value of our study is to reassure women, clinicians, and screening guidelines committees that the benefi ts of testing for HPV identifi ed in clinical trials and research cohorts, which might not represent routine clinical practice in a general population, are indeed noted in general practice with all its attendant complexities.
However, the KPNC experience might be diffi cult to apply to substantially diff erent screening programmes. For example, most women at KPNC with abnormal cytology were referred for colposcopy at enrolment, but almost three-quarters of women positive for HPV had normal cytology and few of them were referred for colposcopy at enrolment. Thus, an alternate screening programme that sends more women positive for HPV but negative by Pap to colposcopy would probably report greater risk of CIN3 or worse at enrolment than we did in KPNC. For another example, although we recorded low 5-year cancer rates in women negative by both HPV and Pap testing, a programme that actually implements a 5-year screening interval for these women would record a slightly higher cancer rate than that noted in KPNC because the second co-test at 3 years, although having little eff ect, still excised the few CIN2 or CIN3 lesions that could have progressed to cancer in 2 years. For a fi nal example, the cancer risk for all women negative for HPV in a primary HPV testing programme, where all women negative for HPV have extended screening intervals, should be somewhat higher than the cancer risk in all women negative for HPV in KPNC, because KPNC referred the 0·5% of women negative for HPV with LSIL or worse abnormalities for colposcopy where excision of CIN2 or CIN3 lesions might have prevented a few future cancers.
In summary, our fi ndings show that adding HPV testing to cytology screening promoted earlier identifi cation of the women at high risk of cervical cancer (especially adenocarcinoma) and allowed safe 3-year screening intervals for women negative by both HPV and
Panel: Research in context
Systematic review
Evidence from long-term prospective cohorts and randomised clinical trials shows that incorporating testing for HPV into cervical cancer screening programmes could reduce cervical cancer incidence in women 30 years and older [4] [5] 8, 10 and even cervical cancer mortality. 12 Cohorts and trials suggest that women's risk of cervical intraepithelial neoplasia grade 3 (CIN3) or cancer after a negative HPV test is very low for 5 years, 3, 10, 13, 14 although these studies were too small to reliably estimate risk of cancer itself. This evidence was the basis for regulatory and clinical guideline approval 15, 16 of routine HPV testing in conjunction with cervical cytology (co-testing) for cervical cancer screening of women 30 years and older. In particular, the guidelines discourage screening of women testing negative for HPV with normal cytology before 3 years to avoid detection of new infections with HPV because their cancer risk is probably low. Although very promising, co-testing has not been widely adopted in the USA. In a recent survey, less than a fi fth of US clinicians would recommend the 3-year screening interval for women testing negative for HPV with normal cytology. 18 These facts suggested to us that there remains serious concern about the safety of co-testing guidelines against cancer in real-life clinical practice. To address this issue, we collaborated with a health-care provider that serves a population large enough to directly estimate cancer risks for even the lowest-risk women undergoing co-testing.
Interpretation
Previous clinical trials and research cohorts showed that HPV testing can prevent CIN3 or worse in tightly-controlled, research settings, but it remained unclear if HPV testing could prevent cancer in a real-life clinical setting. Our fi ndings showed that women testing negative for HPV had extremely low risk of developing cervical cancer over 5 years, so low that it was similar to their risk of developing vulvar cancer, a cancer that is thought too rare to justify screening. Therefore, the 3-year screening interval for women testing negative for HPV with a normal Pap test is safe in routine clinical practice. Furthermore, testing positive for HPV identifi ed more women at enrolment who developed cervical cancer, and especially cervical adenocarcinoma, an uncommon but particularly lethal form of cervical cancer whose precursors are poorly-identifi ed by Pap tests. The earlier identifi cation of these women by HPV testing can facilitate earlier treatment and closer monitoring of high-risk women. In particular, women positive for HPV with normal cytology accrued substantial risk of cancer over 5 years and require stringent follow-up.
Pap testing that reduced the burden of screening on patients and clinicians. Furthermore, our fi ndings suggest that 5-year screening intervals for women negative by both HPV and Pap testing might be safe and that HPV testing without adjunctive cytology might be suffi ciently sensitive for primary cervical cancer screening. The results of co-testing in 330 000 women over 5 years at KPNC defi nitively shows that concurrent HPV testing and cytology can be feasibly implemented in routine clinical practice to provide powerful prevention of cervical cancer (panel).
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